For your patients with metastatic castration-resistant prostate cancer (mCRPC), YONSA® may be the right treatment option
YONSA is the first and only micronized abiraterone acetate formulation approved by the FDA, when taken with methylprednisolone.1-3
5 reasons to reach for YONSA
1. Therapeutic equivalence: Thanks to the increased surface area and improved absorption, YONSA is the only FDA-approved abiraterone acetate approved at a 500-mg dose1-3
2. Significant improvements in overall survival vs placebo (14.8 months vs 10.9 months, respectively, P<0.0001)1*†
3. Time to chemotherapy 50% longer than with placebo (25.2 months vs 16.8 months, respectively, P<0.0001)1*‡
4. Lower dose, similar effect: YONSA taken at a 500-mg dose with methylprednisolone provides similar bioavailability to 1000 mg of abiraterone acetate with corticosteroid4
5. PA assistance: Helping your office navigate the PA process and remove obstacles to coverage
For more information on ways to expedite PAs, click here
ADVERSE REACTIONS
The most common adverse reactions (≥10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.
The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.
Please see additional Important Safety Information below.
Watch a panel of mCRPC experts discuss:
- Treatment
- Prior authorizations
- Practical benefits of YONSA
*Study conducted using conventional formulation of abiraterone acetate. In a separate study, 500 mg of YONSA® showed similar bioavailability to 1000 mg of the conventional formulation.
†Study design: In a randomized, placebo-controlled, multicenter phase 3 clinical trial, patients with mCRPC who had received prior docetaxel chemotherapy received abiraterone acetate at a dose equivalent to YONSA® 500 mg once daily in combination with methylprednisolone twice daily (N=797), or placebo (N=398).2
‡In a study of 1088 patients with mCRPC who had not received prior cytotoxic chemotherapy, subjects received abiraterone acetate at a dose equivalent to YONSA® 500 mg once daily in combination with a different corticosteroid twice daily (N=546) or placebo once daily with corticosteroid twice daily (N=542).
YONSA® may not be interchangeable with other abiraterone acetate products. To avoid substitution errors and overdose, be aware that YONSA® tablets may have different dosing and food effects than other abiraterone acetate products.1
INDICATION
YONSA® (abiraterone acetate) in combination with methylprednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
CONTRADICTIONS: None
IMPORTANT SAFETY INFORMATION
To avoid medication errors and overdose, be aware that YONSA® tablets may have different dosing and food effects than other abiraterone acetate products.
Patients receiving YONSA® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
WARNINGS AND PRECAUTIONS
Mineralocorticoid excess: Closely monitor patients with cardiovascular disease. Control hypertension and correct hypokalemia before treatment. Monitor blood pressure, serum potassium and symptoms of fluid retention at least monthly.
Adrenocortical insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency. Adrenocortical insufficiency was reported in patients receiving abiraterone acetate in combination with corticosteroid, following an interruption of daily steroids and/or with concurrent infection or stress. Increased dosage of corticosteroids may be indicated before, during and after stressful situations.
Hepatotoxicity: Can be severe and fatal. Monitor liver function and modify, interrupt, or discontinue YONSA® dosing as recommended. In post-marketing experience, there has been abiraterone acetate-associated severe hepatic toxicity, including reports of fulminant hepatitis, acute liver failure, and deaths.
Increased fractures and mortality in combination with radium Ra 223 dichloride: Use of YONSA® plus methylprednisolone in combination with radium Ra 223 dichloride is not recommended.
Embryo-Fetal toxicity: YONSA® can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during YONSA® use and for 3 weeks after the final dose of YONSA®. Females who are pregnant or may be pregnant should not handle YONSA® tablets if broken, crushed, or damaged without protection, eg, gloves.
Hypoglycemia: Severe hypoglycemia has been reported in patients with pre-existing diabetes who are taking medications containing thiazolidinediones (including pioglitazone) or repaglinide. Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required.
ADVERSE REACTIONS
The most common adverse reactions (≥10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection, and contusion.
The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT, and hypokalemia.
DRUG INTERACTIONS
Effect of other Drugs on YONSA®
Strong CYP3A4 Inducers:
The co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during YONSA® treatment. If a strong CYP3A4 inducer must be co-administered, increase the YONSA® dosing frequency.
Effects of YONSA® on other Drugs
CYP2D6 Substrates:
Abiraterone is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug in accordance with its Prescribing Information.
CYP2C8 Substrates:
Abiraterone is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. Patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with abiraterone acetate.
To Report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
Please see Full Prescribing Information.
References: 1. YONSA® [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. 2. Goldwater R, Hussaini A, Bosch B, Nemeth P. Comparison of a novel formulation of abiraterone acetate vs. the originator formulation in healthy male subjects: two randomized, open-label, crossover studies. Clin Pharmacokinet. 2017;56(7):803-813. 3. Zytiga® [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 4. Hussaini A, Olszanski AJ, Stein CA, Bosch B, Nemeth P. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemother Pharmacol. 2017;80(3):479-486.
© 2026 Sun Pharmaceutical Industries, Inc. All rights reserved. YONSA is a registered trademark of Sun Pharmaceutical Industries Limited.
PM-US-YON-0915 02/2026